Cantor Fitzgerald Predicts STOK FY2026 Earnings

Stoke Therapeutics, Inc. (NASDAQ:STOK) – Cantor Fitzgerald issued their FY2026 earnings estimates for Stoke Therapeutics in a research report issued on Monday, June 9th. Cantor Fitzgerald analyst P. Stavropoulos anticipates that the company will post earnings of ($2.51) per share for the year. Cantor Fitzgerald has a “Strong-Buy” rating on the stock. The consensus estimate for Stoke Therapeutics’ current full-year earnings is ($2.01) per share.

Stoke Therapeutics (NASDAQ:STOK) last posted its earnings results on Monday, March 24th. The company reported ($0.18) earnings per share for the quarter, beating the consensus estimate of ($0.56) by $0.38. Stoke Therapeutics had a negative net margin of 629.90% and a negative return on equity of 54.45%. The business had revenue of $22.61 million for the quarter, compared to analyst estimates of $4.20 million.

STOK has been the topic of a number of other reports. Needham & Company LLC reissued a “buy” rating and set a $22.00 target price on shares of Stoke Therapeutics in a research report on Wednesday, April 9th. Chardan Capital reiterated a “buy” rating and issued a $24.00 price objective on shares of Stoke Therapeutics in a report on Wednesday, March 19th. Finally, HC Wainwright lowered their target price on Stoke Therapeutics from $47.00 to $35.00 and set a “buy” rating for the company in a research note on Wednesday, May 14th. Five research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat.com, Stoke Therapeutics has an average rating of “Buy” and an average price target of $23.20.

Stoke Therapeutics Stock Up 1.2%

NASDAQ STOK opened at $11.50 on Tuesday. Stoke Therapeutics has a fifty-two week low of $5.35 and a fifty-two week high of $17.58. The business has a 50 day moving average price of $9.07 and a two-hundred day moving average price of $9.66. The stock has a market cap of $627.87 million, a PE ratio of -5.48 and a beta of 1.09.

Insiders Place Their Bets

In other Stoke Therapeutics news, insider Barry Ticho sold 6,471 shares of the business’s stock in a transaction on Tuesday, June 3rd. The shares were sold at an average price of $10.03, for a total transaction of $64,904.13. Following the completion of the sale, the insider now owns 25,782 shares in the company, valued at $258,593.46. The trade was a 20.06% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Edward M. Md Kaye sold 10,382 shares of the stock in a transaction on Tuesday, March 18th. The stock was sold at an average price of $8.67, for a total transaction of $90,011.94. Following the sale, the director now directly owns 148,253 shares in the company, valued at $1,285,353.51. This trade represents a 6.54% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 24,748 shares of company stock valued at $225,687 in the last ninety days. Corporate insiders own 11.30% of the company’s stock.

Hedge Funds Weigh In On Stoke Therapeutics

Large investors have recently bought and sold shares of the business. Toronto Dominion Bank bought a new position in Stoke Therapeutics during the 4th quarter worth $35,001,000. RTW Investments LP increased its holdings in shares of Stoke Therapeutics by 10.1% in the 4th quarter. RTW Investments LP now owns 5,123,525 shares of the company’s stock worth $56,512,000 after acquiring an additional 471,240 shares during the period. Checkpoint Capital L.P. lifted its position in Stoke Therapeutics by 139.3% in the 1st quarter. Checkpoint Capital L.P. now owns 730,717 shares of the company’s stock valued at $4,859,000 after purchasing an additional 425,330 shares during the last quarter. Erste Asset Management GmbH acquired a new position in shares of Stoke Therapeutics during the first quarter worth approximately $2,670,000. Finally, Jacobs Levy Equity Management Inc. acquired a new position in Stoke Therapeutics during the 1st quarter worth $2,376,000.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.